What is the oral formulation of Invega Sustenna (paliperidone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Formulation of Invega Sustenna

The oral formulation of Invega Sustenna (paliperidone palmitate long-acting injectable) is Invega (paliperidone extended-release tablets). 1

Key Information

Invega Sustenna is the long-acting injectable (LAI) formulation, while Invega is the oral extended-release tablet formulation—both contain the same active ingredient, paliperidone. 1, 2

Formulation Details

Oral Invega (Paliperidone ER):

  • Available as extended-release tablets using OROS (Oral Osmotic System) technology 3
  • Formulated for once-daily oral administration 4, 3
  • The extended-release design minimizes plasma level fluctuations and allows treatment initiation at clinically effective doses without titration 3

Injectable Invega Sustenna:

  • Contains paliperidone palmitate as a nanocrystal aqueous suspension 2
  • Administered monthly via intramuscular injection (deltoid or gluteal) 2
  • The palmitate ester hydrolyzes to release the active moiety, paliperidone 1

Clinical Relationship

Both formulations contain paliperidone, which is the major active metabolite of risperidone 1, 2. The key difference is the delivery system:

  • Oral tablets provide daily dosing with extended-release kinetics 3
  • Injectable suspension provides monthly dosing with sustained release over approximately 4 weeks 2

Important Distinction

Paliperidone (9-hydroxyrisperidone) is chemically distinct from its parent compound risperidone, with differences in metabolism (predominantly renal vs. hepatic), protein binding, and drug interaction potential 3. However, both the oral and injectable formulations deliver the same active antipsychotic agent—paliperidone.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.